Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 15, 2019

View Archived Issues

Radiosensitivity can be restored in advanced cancers

New systemic bioluminescent cell line xenograft models for drug discovery in hematologic cancers

Inhibition of fatty acid synthase with FT-4101 reduces hepatic de novo lipogenesis in healthy adults

Merck & Co.'s MK-5890 shows acceptable safety profile and early antitumor activity

Aged gut microbiota transplants show benefits in young mice

Nouscom initiates phase I study of NOUS-209 in microsatellite unstable solid tumors

Sansheng's clinical trial application for HIF-117 capsules cleared in China

Arthrosi Therapeutics presents preclinical and phase I results for AR-882

Cerveau Technologies starts Japanese phase I study of [18F]MK-6240

First patient dosed in phase Ib/IIa proof-of-concept study of BRII-179

Hoth Therapeutics initiates preclinical testing of topical aprepitant

Gilead presents phase II results for selgantolimod in patients with chronic HBV

Preliminary phase I/II data for BMS-986148 monotherapy and combination with nivolumab

Preclinical data suggest MCLA-129 has potential for NSCLC resistant to EGFR-targeted therapies

Janssen describes compounds for respiratory syncytial virus infections

ViiV Healthcare synthesizes prodrugs of HIV maturation inhibitors

New mu-opioid receptor agonists identified at Sichuan Kelun-Biotech Biopharmaceutical

Pfizer patents cyclin-dependent kinase inhibitors

New IDO-1 inhibitors identified at Phenex Discovery Verwaltungs

Results from SILK cohort evaluating tesevatinib in ADPKD patients presented at Kidney Week

Phase II study of AV-101 in major depressive disorder does not meet primary endpoint

I-Mab obtains Chinese IND clearance for phase I trials of TJM-2 in rheumatoid arthritis

FDA approves Fetroja for complicated urinary tract infections

FDA grants accelerated approval to Brukinsa for mantle cell lymphoma

Interim data presented from phase I study of TK-216 in Ewing's sarcoma

resTORbio stops development of RTB-101 for clinically symptomatic respiratory illness

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...